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There has been a drastic change in the therapeutic strategy 
for patients with metastatic melanoma over last 7 years. 
Since 2011, the US Food and Drug Administration (FDA) 
has approved a number of drugs for advanced disease, 
including multi-drug combinations. Overall, the 1-year 
survival rate shifted from 25% to an impressive 75% (1). 
In large randomized phase III trials (RCTs), targeting 
mutations in BRAF-MEK-ERK pathway or inhibiting 
the cytotoxic T lymphocyte antigen-4 (CTLA-4) and 
the programmed cell death protein 1 (PD-1) have been 
shown to achieve a high rate of durable response, when 
used as first, second line and over; this lead to 2-year and 
3-year survival rates above 50% and between 40% and 
50% respectively (2,3). While waiting for mature overall 
survival (OS) data of the newest combinations, we have 
seen a 25% of patients with stage IV melanoma being 
cured with immunotherapy, a previously unobserved result; 
however, still more than half of patients are going to die for 
progressive disease, and we need to continuously explore 
new strategies and combination in order to maximize the 
long-term cure rate.
The brain is a prominent site of treatment failure for 
metastatic melanoma, and one-third of patients will develop 
intra-cranial disease; median survival time for these patients 
was generally poor, ranging from 3 to 5 months (4). As 
most of the largest RCTs testing BRAF inhibitors and 
immunotherapy excluded patients with active melanoma 
brain metastases (MBM), the real impact of immunotherapy 
and targeted agents on outcomes of MBM patients is still 
unclear.
At this regard, Sloot and colleagues (5) recently 
reported the results of an extensive retrospective cohort 
study including patients who received systemic therapy 
for advanced melanoma, where incidence and survival of 
patients with MBM were investigated and compared with 
a cohort of melanoma patients without MBM, and authors 
should be congratulated for their effort in exploring this 
particular setting providing new data.
Notably, the primary endpoint of this study was to 
investigate for the possible effect of different regimens on 
de novo MBM development, in patients either treated with 
chemotherapy, bio-chemotherapy, IL-2, anti-BRAF agents 
or immune checkpoint inhibitors. The secondary endpoint 
was to compare OS in patients with and without MBM and 
confirm and/or identify new prognostic factors. The main 
value of the study is that it offers a cross-sectional picture of 
“real-life” clinical advances for patients with MBM trough 
the last decades and provides interesting new insights into 
the natural history of the brain metastases when anti-BRAF 
and immunotherapy are used.
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between 2000 and 2012 was analyzed. A total of 1,016 
patients were initially evaluated for inclusion into this 
data set; exclusion criteria were: (I) <2 months of follow-
up time (245 patients); (II) no digital records available (116 
patients); (III) nonmelanoma cancer diagnosis (40 patients); 
(IV) multiple melanoma primary tumors (4 patients); (V) 
missing date of diagnosis (one patient). Finally, 610 patients 
have been included for analysis. The majority of them, 
367 (60.2%), did not have or develop MBM, while 243 
(39.8%) had MBM: among them, 166 (68.3%) developed 
intracranial disease while on treatment, and 77 (31.7%) 
at diagnosis. The first brain failure event was most often 
detected during the first-line therapy (35.4%).
Patients have been then stratified into three groups, 
according to the time when targeted therapies were 
introduced (2000–2008, 2009–2010 and from 2011 
onward). Between 2009 and 2010, an increasing number of 
checkpoint/targeted therapy trials became available and 2011 
was the year ipilimumab and vemurafenib were approved.
First, the results confirmed for MBM few known 
prognostic factors: a limited number of brain metastases 
(n<4), the absence of neurological symptoms and a better 
Karnofsky performance status (>70–90) all resulted to 
be associated with longer OS. As expected, a global 
significant different in OS was observed between patients 
with and without MBM, with median of 25.9 and 
35.5 months, respectively (P=0.048). Among MBM patients, 
the probability of survival at 1, 2 and 3 years was 79.7% 
(95% CI, 76.3–82.7%), 60.6% (95% CI, 56.3–64.6%) and 
45.9% (95% CI, 41.4–50.3%), respectively. To be noted, 
median OS was 22.7 months in MBM patients diagnosed 
from 2011, compared with 8.5 and 7.5 months for MBM 
patients diagnosed between 2009–2010 and 2000–2008 
(P=0.0002), respectively. In line with these findings, the 
receipt of BRAF-targeted therapy or immune checkpoint 
inhibitors or the combination of both were all associated 
with improved OS when tested at multivariate Cox analysis 
(see supporting information on table 4). A longer OS 
was also found for patients who were treated locally at 
the time of MBM detection, highlighting the impact of 
local therapies even when combined with more effective 
systemic agents [hazard ratio (HR) 3.5, P=0.00038]. The 
most frequent treatment for MBM was radiosurgery 
[stereotactic radiosurgery (SRS)] (48.6%), followed by 
whole-brain radiotherapy (WBRT) (15.6%), neurosurgery 
(15.2%) and starting/continuation of systemic treatments 
(2.2%); 5.4% received no treatment, and the remainder 
(13%) received a combination of radiosurgery and whole 
brain irradiation. So, most of the patients received a brain-
directed radiotherapy upfront (77.2%).
Focusing on the primary endpoint, the overall incidence 
of de novo MBM among the whole cohort was 40%, 
comparable to historical datasets (6). Moreover, despite 
the higher OS observed for MBM patients diagnosed after 
2011, the incidence of de novo MBM did not significantly 
differ between those receiving either BRAF-targeted agents, 
ipilimumab or anti PD-1/PD-L1 therapies in comparison 
with traditional chemotherapy. This finding is somehow 
confounding, being possibly an effect of a selection bias, as 
probably the patients included in this observational study 
who were treated with experimental agents (anti BRAF-
MEK or immunotherapy) underwent more extensive 
follow-up brain imaging in comparison to patients receiving 
chemotherapy, increasing the detection rate of MBM. 
Once diagnosed, MBM were more efficiently controlled 
after 2011, and the effect on survival might be composite, 
being possibly linked to the higher efficacy of new agents, 
to advances in brain imaging (use of brain MRI) and/
or to a wider use of local therapies such as radiosurgery 
through time. These are typical confounding factors of a 
retrospective analysis and cannot be separately evaluated. 
The higher efficacy in controlling MBM of both anti-BRAF 
therapies and immunotherapy was independently shown 
by three prospective trials, which reported the highest 
intracranial response rate for MBM so far. The COMBI-
MB trial (7), a multicohort phase II trial including patients 
with showed in BRAFV600E-mutated MBM, achieved an 
overall response rate (ORR) of 58% (95% CI, 46–69%) 
and the 6-month progression-free survival (PFS) was 44% 
(95% CI, 32–56%) in asymptomatic patients receiving 
dabrafenib and trametinib as first therapy for MBM. Long 
and colleagues (8) then reported the results of a randomized 
phase II trial designed with the aim of investigating 
the intracranial response rate in asymptomatic and 
immunotherapy naïve MBM treated with the combination 
of Nivolumab and Ipilimumab vs. Nivolumab alone. The 
trial showed a substantial efficacy of immunotherapy when 
used upfront, with a 46% (95% CI, 29–63%) intracranial 
ORR for the combination vs. 20% (95% CI, 7–41%) for the 
single agent, respectively, with a remarkable 6-month PFS 
of 53% (95% CI, 38–73%). The high response duration 
achieved by Nivolumab combined with Ipilimumab was 
also disclosed by the single arm phase II Checkmate 204 
trial, with preliminary data reporting a 6-month PFS of 
67% (9). Waiting for the survival results, these trials could 
establish a new benchmark for this population; however, 
3Translational Cancer Research, 2018
© Translational Cancer Research. All rights reserved.   Transl Cancer Res 2018 tcr.amegroups.com
toxicity is an issue, and the integration with local therapies 
such as radiosurgery is yet to be explored. At this regard, 
the significative longer OS in patients primarily treated 
with local therapy after the diagnosis of MBM is one of 
the most interesting findings in the article by Sloot et al. A 
progressive change occurred in the use of RT for MBM, 
from palliative WBRT to multiple repeated SRS. Detailed 
data are lacking on this specific point, as tracking brain 
progression was beyond the scope of the investigation, but 
we argue that the combination of multiple SRS and single 
agent immunotherapy, given also potential synergistic 
effects and safety, is worth of investigation, and prospective 
trials are ongoing (10). In the meantime, given the large 
amount of retrospective data indicating the safety and 
efficacy of this approach (for instance SRS followed by anti-
PD-1), this strategy is common in many centers worldwide. 
On the other front, the combination with BRAF inhibitors 
and SRS is to be regarded with caution, given the higher 
reported rate of unexpected toxic events (10).
In our opinion, the main message from the observational 
study by Sloot and collaborators is that the change in 
outcome for MBM patients achieved after the introduction 
of targeted therapy and immunotherapy appears clearly 
evident in “real life”; this very positive phenomenon should 
be taken into account both at diagnosis and progression, 
omitting WBRT in favor of more conservative approaches, 
possibly combining in sequence multiple options and 
keeping in mind the possible long-term survival as well as 
the potential treatment-related morbidity. Information on 
the best sequence, and the combined use of local therapies 
and immunotherapy, will hopefully come from ongoing and 
future trials. 
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